For research use only. Not for therapeutic Use.
NCGC00092410 is a potent, selective, and nonsugar glucocerebrosidase (GC) inhibitor, with an IC50 of 31 nM. NCGC00092410 shows no activity against the related hydrolases at concentrations up to 77 μM. NCGC00092410, a GC chaperone, and increases the activity and lysosomal localization of glucocerebrosidase in mutant cell lines. NCGC00092410 can be used for the research of Gaucher disease[1].
NCGC00092410 (7.3-130 nM; 25 min) inhibits the GC activity at various substrate concentrations (10-150 μM) in a dose-dependent manner[1].
NCGC00092410 (55-40 μM; 2 d) increases the GC activity in the N370S mutant fibroblasts[1].
NCGC00092410 (40 μM; 60-72 h) increases the lysosomal localization of GC in gaucher fibroblasts[1].
| Catalog Number | I032410 |
| CAS Number | 442898-34-2 |
| Synonyms | N-(4-methyl-2-morpholin-4-ylquinolin-6-yl)cyclohexanecarboxamide |
| Molecular Formula | C21H27N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H27N3O2/c1-15-13-20(24-9-11-26-12-10-24)23-19-8-7-17(14-18(15)19)22-21(25)16-5-3-2-4-6-16/h7-8,13-14,16H,2-6,9-12H2,1H3,(H,22,25) |
| InChIKey | BXVNPOBNVRBOOV-UHFFFAOYSA-N |
| SMILES | CC1=CC(=NC2=C1C=C(C=C2)NC(=O)C3CCCCC3)N4CCOCC4 |
| Reference | [1]. Zheng W, et, al. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13192-7. |
